Malaria continued to be a deadly situation for the people of tropical and subtropical
countries. Although there has been a marked reduction in new cases as well as mortality …

Multidrug resistance has rendered monotherapy for malaria useless in most parts of the
world, and has also compromised the usefulness of many of the available combination …

We reside in an era of technological innovation and advancement despite which infectious
diseases like malaria remain to be one of the greatest threats to the humans. Mortality rate …

Background Artemisinin-based combination therapies (ACTs) are the mainstay for the
management of uncomplicated malaria cases. However, up-to-date data able to assist sub …

It has been demonstrated that fosmidomycin has good tolerability and rapid onset of action,
but late recrudescences preclude its use alone; in vitro, clindamycin has been shown to act …

Recrudescent Plasmodium falciparum parasites were sampled from 108 children taking part
in a drug efficacy trial in Gabon. A finger-prick blood sample was taken from each child …

Fosmidomycin-clindamycin therapy given every 12 h for 3 days was compared with a
standard single oral dose of sulfadoxine-pyrimethamine. The two treatments showed …

The study of molecular markers of drug resistance is particularly important in surveillance
studies of drugs, such as mefloquine, that still retain efficacy in sub-Saharan Africa yet have …

Drug combination therapies have been devised to delay the development and spread of
resistant malaria parasites. However, poor design often leads to ineffective combinations …

Background Use of anti-malarial medication in children is hampered by a paucity of dosage,
pharmacokinetic and tolerability data. Methods Data on the use of mefloquine in children …